{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.8","upperLimit":"202.2","value":"138"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"EFS is defined as time from the start of the treatment until the first date that criteria for progressive disease are met, therapy was discontinued for toxicity, or death, whichever occurs first. Those patients alive will be censored at the date of last clinical contact. If progression is based upon serum or urine paraprotein measurements, which must be repeated for confirmation, event-free progression is still measured from the start of treatment until the first date that progression is detected.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.\n\nIn patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.","id":"OG000","title":"Dasatinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Completion of treatment (median duration of therapy was 51 days)","title":"Event-free Survival (EFS) for Participants With Plateau Phase Disease","type":"SECONDARY","unitOfMeasure":"days"}